Advertisement

Inflammation Research

, Volume 61, Issue 4, pp 285–292 | Cite as

The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures

  • Michael J. Monument
  • David A. Hart
  • A. Dean Befus
  • Paul T. Salo
  • Mei Zhang
  • Kevin A. Hildebrand
Original Research Paper

Abstract

Objectives

Using a rabbit model of post-traumatic joint contractures, we investigated whether treatment with a mast cell stabilizer after joint injury would lessen the molecular manifestations of joint capsule fibrosis.

Methods

Surgical joint injury was used to create stable post-traumatic contractures of the knee in skeletally mature New Zealand white rabbits. Four groups of animals were studied: a non-operated control group (n = 8), an operated contracture group (n = 13) and two operated groups treated with the mast cell stabilizer, ketotifen, at doses of 0.5 mg/kg (n = 9) and 1.0 mg/kg (n = 9) twice daily. Joint capsule fibrosis was assessed by quantifying the mRNA and protein levels of α-SMA, tryptase, TGF-β1, collagen I and collagen III. Significance was tested using an ANOVA analysis of variance.

Results

The protein and mRNA levels of α-SMA, TGF-β1, tryptase and collagen I and III were significantly elevated in the operated contracture group compared to control (p < 0.01). In both ketotifen-treated groups, protein and mRNA levels of α-SMA, TGF-β1 and collagen I were significantly reduced compared to the operated contracture group (p < 0.01).

Conclusions

These data suggest an inflammatory pathway mediated by mast cell activation is involved in joint capsule fibrosis after traumatic injury.

Keywords

Ketotifen Mast cells Fibrosis Rabbit Post-traumatic 

Notes

Acknowledgments

We would like to thank the Canadian Orthopaedic Foundation for their generous funding of this project via the Robert Salter Award. D.A.H. is the Calgary Foundation–Grace Glaum Professor. All authors have no financial affiliations to disclose regarding this research.

References

  1. 1.
    Lindenhovius AL, Jupiter JB. The posttraumatic stiff elbow: a review of the literature. J Hand Surg Am. 2007;32:1605–23.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen MS, Hastings IH. Post-traumatic contracture of the elbow. Operative release using a lateral collateral ligament sparing approach. J Bone Joint Surg Br. 1998;80B:805–12.CrossRefGoogle Scholar
  3. 3.
    Gallay SH, Richards RR, O’Driscoll SW. Intraarticular capacity and compliance of stiff and normal elbows. Arthroscopy. 1993;9:9–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Cohen MS, Schimmel DR, Masuda K, Hastings H 2nd, Muehleman C. Structural and biochemical evaluation of the elbow capsule after trauma. J Shoulder Elbow Surg. 2007;16:484–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Hildebrand KA, Zhang M, Hart DA. High rate of joint capsule matrix turnover in chronic human elbow contractures. Clin Orthop Relat Res. 2005;439:228–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Hildebrand KA, Zhang M, van Snellenberg W, King GJ, Hart DA. Myofibroblast numbers are elevated in human elbow capsules after trauma. Clin Orthop Relat Res. 2004;419:189–97.PubMedCrossRefGoogle Scholar
  7. 7.
    Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem. 1995;270:3423–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol. 2001;24:591–8.PubMedGoogle Scholar
  9. 9.
    Harunari N, Zhu KQ, Armendariz RT, Deubner H, Muangman P, Carrougher GJ, et al. Histology of the thick scar on the female, red Duroc pig: final similarities to human hypertrophic scar. Burns. 2006;32:669–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200:500–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Vaughan MB, Howard EW, Tomasek JJ. Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res. 2000;257:180–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Hildebrand KA, Zhang M, Hart DA. Myofibroblast upregulators are elevated in joint capsules in posttraumatic contractures. Clin Orthop Relat Res. 2007;456:85–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Heard BE, Dewar A, Corrin B. Apposition of fibroblasts to mast cells and lymphocytes in normal human lung and in cryptogenic fibrosing alveolitis. Ultrastructure and cell perimeter measurements. J Pathol. 1992;166:303–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Gruber BL. Mast cells in the pathogenesis of fibrosis. Curr Rheumatol Rep. 2003;5:147–53.PubMedCrossRefGoogle Scholar
  15. 15.
    Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs. 1990;40:412–48.PubMedCrossRefGoogle Scholar
  16. 16.
    Torkildsen GL, Abelson MB, Gomes PJ. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis. Clin Ther. 2008;30:1272–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Gallant-Behm CL, Hildebrand KA, Hart DA. The mast cell stabilizer ketotifen prevents development of excessive skin wound contraction and fibrosis in red Duroc pigs. Wound Repair Regen. 2008;16:226–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Monument MJ, Hart DA, Befus AD, Salo PT, Zhang M, Hildebrand KA. The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: a study of a rabbit model of posttraumatic joint contractures. J Bone Joint Surg Am. 2010;92:1468–77.PubMedCrossRefGoogle Scholar
  19. 19.
    Hildebrand KA, Sutherland C, Zhang M. Rabbit knee model of post-traumatic joint contractures: the long-term natural history of motion loss and myofibroblasts. J Orthop Res. 2004;22:313–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Martin U, Romer D. The pharmacological properties of a new, orally active antianaphylactic compound: ketotifen, a benzocycloheptathiophene. Arzneimittelforschung. 1978;28:770–82.PubMedGoogle Scholar
  21. 21.
    Craps LP, Ney UM. Ketotifen: current views on its mechanism of action and their therapeutic implications. Respiration. 1984;45:411–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Chiang CH, Chen JL, Liu YT, Wang DP. Therapeutic effect and pharmacokinetics of ketotifen transdermal delivery system. Drug Dev Ind Pharm. 1998;24:213–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Hildebrand KA, Zhang M, Germscheid NM, Wang C, Hart DA. Cellular, matrix, and growth factor components of the joint capsule are modified early in the process of posttraumatic contracture formation in a rabbit model. Acta Orthop. 2008;79:116–25.PubMedCrossRefGoogle Scholar
  24. 24.
    Reno C, Marchuk L, Sciore P, Frank CB, Hart DA. Rapid isolation of total RNA from small samples of hypocellular, dense connective tissues. Biotechniques. 1997;22:1082–6.PubMedGoogle Scholar
  25. 25.
    Hildebrand KA, Zhang M, Hart DA. Joint capsule matrix turnover in a rabbit model of chronic joint contractures: correlation with human contractures. J Orthop Res. 2006;24:1036–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Parreno J, Buckley-Herd G, de-Hemptinne I, Hart DA. Osteoblastic MG-63 cell differentiation, contraction, and mRNA expression in stress-relaxed 3D collagen I gels. Mol Cell Biochem. 2008;317:21–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Banovac K, Renfree K, Makowski AL, Latta LL, Altman RD. Fracture healing and mast cells. J Orthop Trauma. 1995;9:482–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Lindholm R, Lindholm S, Liukko P, Paasimaki J, Isokaanta S, Rossi R, et al. The mast cell as a component of callus in healing fractures. J Bone Joint Surg Br. 1969;51:148–55.PubMedGoogle Scholar
  29. 29.
    Trabucchi E, Radaelli E, Marazzi M, Foschi D, Musazzi M, Veronesi AM, et al. The role of mast cells in wound healing. Int J Tissue React. 1988;10:367–72.PubMedGoogle Scholar
  30. 30.
    Hildebrand KA, Zhang M, Hart DA. Joint capsule mast cells and neuropeptides are increased within 4 weeks of injury and remain elevated in chronic stages of posttraumatic contractures. J Orthop Res. 2008;26:1313–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Pennington D, Thomas P, Lopez A, Gold W. Transforming growth factor-beta production by dog mastocytoma cells. Storage and release from mast cell granules. Chest. 1991;99:66S.PubMedCrossRefGoogle Scholar
  32. 32.
    Kanbe N, Kurosawa M, Nagata H, Yamashita T, Kurimoto F, Miyachi Y. Production of fibrogenic cytokines by cord blood-derived cultured human mast cells. J Allergy Clin Immunol. 2000;106:S85–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Gushchin IS, Zebrev AI. Ketotifen-induced histamine release, inhibition of histamine secretion and modulation of immune response. Agents Actions. 1986;18:92–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Shiratori Y, Takada H, Hai K, Kiriyama H, Mawet E, Komatsu Y, et al. Effect of anti-allergic agents on chemotaxis of neutrophils by stimulation of chemotactic factor released from hepatocytes exposed to ethanol. Dig Dis Sci. 1994;39:1569–75.PubMedCrossRefGoogle Scholar
  35. 35.
    Akers IA, Parsons M, Hill MR, Hollenberg MD, Sanjar S, Laurent GJ, et al. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am J Physiol Lung Cell Mol Physiol. 2000;278:L193–201.PubMedGoogle Scholar
  36. 36.
    Gailit J, Marchese MJ, Kew RR, Gruber BL. The differentiation and function of myofibroblasts is regulated by mast cell mediators. J Invest Dermatol. 2001;117:1113–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Sekardi L, Friedberg KD. Inhibition of immunological histamine release from guinea pig lungs and other organs by mepyramine, ketotifen, and picumast in vivo. Arzneimittelforschung. 1989;39:1331–5.PubMedGoogle Scholar
  38. 38.
    Radermecker M. Inhibition of allergen-mediated histamine release from human cells by ketotifen and oxatomide. Comparison with other H1 antihistamines. Respiration. 1981;41:45–55.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2011

Authors and Affiliations

  • Michael J. Monument
    • 1
  • David A. Hart
    • 1
  • A. Dean Befus
    • 2
  • Paul T. Salo
    • 1
  • Mei Zhang
    • 1
  • Kevin A. Hildebrand
    • 3
  1. 1.Division of Orthopaedic Surgery, Faculty of MedicineMcCaig Institute for Bone and Joint Health, University of CalgaryCalgaryCanada
  2. 2.Department of Medicine, Pulmonary Research GroupUniversity of AlbertaEdmontonCanada
  3. 3.Division of Orthopaedic Surgery, Faculty of MedicineMcCaig Institute for Bone and Joint Health, University of CalgaryCalgaryCanada

Personalised recommendations